CytRx Corp. (Nasdaq: CYTR) reported positive interim results from a Phase 2 study of aldoxorubicin to treat brain cancer lifting the stock price 57 cents to $3.42.
CytRx reports positive interim results
January 06, 2015 at 13:32 PM EST
CytRx reports positive interim resultsJanuary 06, 2015 at 13:32 PM EST
CytRx Corp. (Nasdaq: CYTR) reported positive interim results from a Phase 2 study of aldoxorubicin to treat brain cancer lifting the stock price 57 cents to $3.42.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|